Bullish short-squeeze thesis on ImmunityBio (IBRX) citing ~40% short interest, rising cost to borrow, and a string of positive catalysts including NSCLC data and Saudi FDA approval.
IBRX — LONG The author argues IBRX is set up for a short squeeze with ~40% of float shorted (~120M shares) and ~10 days to cover, so a volume spike would trap shorts. Catalysts cited include Jan 13 positive NSCLC data, Jan 14 Saudi FDA approval, and pending glioblastoma and CAR-NK data, with the Chairman promising multiple press releases. Fundamentals cited: revenue up 424% YoY to $32.1M on ANKTIVA ramp and $257M cash removing bankruptcy risk. The author's stated condition is that a break and hold of $3.00 triggers the move.
IBRX is the perfect setup for an insane short squeeze. We have the perfect squeeze data along with some crazy catalysts, plus it’s actually a great company.
This Reddit post, published January 15, 2026, features u/Bailey-96 discussing IBRX. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Bailey-96 · Tickers: IBRX